HUTCHMED Highlights Sovleplenib Phase III Data

Summary by AI BETAClose X

HUTCHMED announced positive Phase III data for sovleplenib in warm antibody autoimmune hemolytic anemia (wAIHA) presented at the EHA Congress, showing a significantly higher durable response rate of 66% versus 15% for placebo (p<0.0001) and a 70% overall response rate compared to 22% for placebo (p<0.0001). The study also demonstrated a significant reduction in rescue therapy use (16% vs 54%, p=0.0001) and blood transfusions (11% vs 43%), with a favorable safety profile where Grade ≥3 treatment-emergent adverse events occurred in 43% of the sovleplenib arm versus 59% in the placebo arm. This data supports the New Drug Application for sovleplenib, which has been accepted for review with priority status by the China National Medical Products Administration.

Disclaimer*

UK 100

Latest directors dealings